User profiles for Daniela De Angelis
 | Daniela De AngelisProgramme Leader, Medical Research Council Biostatistics Unit, Cambridge Verified email at mrc-bsu.cam.ac.uk Cited by 10269 |
Modeling infectious disease dynamics in the complex landscape of global health
BACKGROUND Despite many notable successes in prevention and control, infectious
diseases remain an enormous threat to human and animal health. The ecological and …
diseases remain an enormous threat to human and animal health. The ecological and …
A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales
OO Aalen, VT Farewell, D De Angelis… - Statistics in …, 1997 - Wiley Online Library
Back‐calculation is a widely used method to estimate HIV incidence rates, and is commonly
based on times of AIDS diagnosis. Following up earlier work, we extend this method to also …
based on times of AIDS diagnosis. Following up earlier work, we extend this method to also …
Risk of hospital admission for patients with SARS-CoV-2 variant B. 1.1. 7: cohort analysis
…, J Flannagan, H Allen, A Charlett, D De Angelis… - bmj, 2021 - bmj.com
Objective To evaluate the relation between diagnosis of covid-19 with SARS-CoV-2 variant
B.1.1.7 (also known as variant of concern 202012/01) and the risk of hospital admission …
B.1.1.7 (also known as variant of concern 202012/01) and the risk of hospital admission …
Prospects of elimination of HIV with test-and-treat strategy
…, PJ Birrell, D De Angelis… - Proceedings of the …, 2013 - National Acad Sciences
Recently, there has been much debate about the prospects of eliminating HIV from high
endemic countries by a test-and-treat strategy. This strategy entails regular HIV testing in the …
endemic countries by a test-and-treat strategy. This strategy entails regular HIV testing in the …
[HTML][HTML] Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission
…, G Dougan, OG Pybus, DD Angelis… - Nature …, 2022 - nature.com
Understanding SARS-CoV-2 transmission in higher education settings is important to limit
spread between students, and into at-risk populations. In this study, we sequenced 482 SARS-…
spread between students, and into at-risk populations. In this study, we sequenced 482 SARS-…
[HTML][HTML] Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a …
…, AC Ghani, SR Seaman, G Dabrera, D De Angelis… - The lancet, 2022 - thelancet.com
Background The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine
escape and high transmissibility, with early studies indicating lower severity of infection …
escape and high transmissibility, with early studies indicating lower severity of infection …
Bayesian emulation and calibration of a dynamic epidemic model for A/H1N1 influenza
…, P Birrell, S Conti, DD Angelis - Journal of the American …, 2014 - Taylor & Francis
In this article, we develop a Bayesian framework for parameter estimation of a computationally
expensive dynamic epidemic model using time series epidemic data. Specifically, we …
expensive dynamic epidemic model using time series epidemic data. Specifically, we …
[HTML][HTML] Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort …
…, E Gallagher, A Charlett, D De Angelis… - The Lancet Infectious …, 2022 - thelancet.com
Background The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March,
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …
Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence
M Hickman, D De Angelis, P Vickerman… - Current opinion in …, 2015 - journals.lww.com
Eliminating HCV through scaling up treatment is a theoretical possibility. But empirical data
are required to demonstrate that HCV treatment can reduce HCV transmission, which will …
are required to demonstrate that HCV treatment can reduce HCV transmission, which will …
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence
…, N Palmateer, M May, A Taylor, D De Angelis… - …, 2011 - Wiley Online Library
Aims To investigate whether opiate substitution therapy (OST) and needle and syringe
programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (…
programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (…
